A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
- 29 Jan 2018 New trial record